Explore practical implications of new research in nephrotic syndrome, from renal biopsy and genetic testing to managing ...

KDIGO's new IgA nephropathy guideline shifts the treatment paradigm from supportive care alone to targeting the disease's immunologic nature.

The Lupus Research Alliance applauds the approval by the U.S. Food and Drug Administration of Gazyva® (obinutuzumab) from ...

Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year -- Second pivotal development ...

The Yobe State Commissioner of Home Affairs, Information and Culture, Hon. Abdullahi Bego, has said that due to many cases of ...

The guideline incorporates the latest advice on diagnosis and treatment, lowering proteinuria targets, and integrating new agents such as nefecon, sparsentan, and SGLT2 inhibitors.

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

Dr Arvind Kohli [email protected] The World Thrombosis Day is the global campaign of the International Society on ...

Phenotyping patients can help to identify potential heart failure with preserved ejection fraction (HFpEF) as well as improve patient outcomes.

Treatments for achondroplasia, acute myeloid leukemia, familial chylomicronemia syndrome, immunoglobulin A nephropathy, and non-small cell lung cancer are under review.

The FDA has approved Genentech’s Gazyva (obinutuzumab) for the treatment of lupus nephritis in adults, according to a news release published today. Gazyva is the first and only anti-CD20 monoclonal ...